Systemic therapy with conventional and novel immunomodulatory agents for ocular inflammatory disease

Khayyam Durrani; Fouad R Zakka; Muna Ahmed; Mohiuddin Memon; Sana S Siddique; C Stephen Foster

doi:10.1016/j.survophthal.2011.05.003

Systemic therapy with conventional and novel immunomodulatory agents for ocular inflammatory disease

Surv Ophthalmol. 2011 Nov-Dec;56(6):474-510. doi: 10.1016/j.survophthal.2011.05.003.

Authors

Khayyam Durrani¹, Fouad R Zakka, Muna Ahmed, Mohiuddin Memon, Sana S Siddique, C Stephen Foster

Affiliation

¹ Massachusetts Eye Research and Surgery Institution, Cambridge, Massachusetts 02142, USA.

PMID: 22117884
DOI: 10.1016/j.survophthal.2011.05.003

Abstract

Ocular inflammatory disease is the third leading cause of blindness in the United States. In addition to the conventional immunomodulatory agents, which include antimetabolites, alkylating agents, and antibiotics such as cyclosporine, many of which have been used in the treatment of this disease for decades, several new treatment modalities have emerged within the past 10 years. We review in detail the characteristics, safety, and efficacy of the conventional immunomodulators, the more novel agents such as the biologics, and investigational drugs that appear promising in the treatment of ocular inflammatory disease.

Publication types

Review

MeSH terms

Algorithms
Humans
Immunologic Factors / adverse effects
Immunologic Factors / therapeutic use*
Keratitis / drug therapy*
Pemphigoid, Benign Mucous Membrane / drug therapy*
Practice Guidelines as Topic
Scleritis / drug therapy*
Uveitis / drug therapy*

Substances

Immunologic Factors